$1.14/ day, billed weekly
Cancel anytime

(Ads Free, Unlimited access)

NO CREDIT CARD REQUIRED

Artiva Biotherapeutics, Inc. Common Stock (ARTV)ARTV

Artiva Biotherapeutics, Inc. Common Stock

$10.96

Delayed price

PASS

BUY Advisory
Profitable SELL
Loss-Inducing SELL

Profit
Loss
PASS (Skip invest)*

Time period over

ALL
YEAR
MONTH
WEEK

Time period over

Upturn Advisory Summary

11/20/2024: ARTV (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance

Type: Stock	Upturn Star Rating	Today’s Advisory: PASS
Historic Profit: -19.34%	Upturn Advisory Performance 1	Avg. Invested days: 17
Profits based on simulation	Stock Returns Performance 1	Last Close 11/20/2024

Type: Stock	Today’s Advisory: PASS
Historic Profit: -19.34%	Avg. Invested days: 17
Upturn Star Rating	Stock Returns Performance 1
Profits based on simulation Last Close 11/20/2024	Upturn Advisory Performance 1

Key Highlights

Company Size Small-Cap Stock	Market Capitalization 274.47M USD
Price to earnings Ratio -	1Y Target Price 21.25
Dividends yield (FY) -	Basic EPS (TTM) -2.48
Volume (30-day avg) 68502	Beta -
52 Weeks Range 9.68 - 17.31	Updated Date 11/20/2024

Company Size Small-Cap Stock	Market Capitalization 274.47M USD	Price to earnings Ratio -	1Y Target Price 21.25
Dividends yield (FY) -	Basic EPS (TTM) -2.48	Volume (30-day avg) 68502	Beta -
52 Weeks Range 9.68 - 17.31	Updated Date 11/20/2024

Earnings Date

Report Date 2024-11-13	When -
Estimate -0.635	Actual -0.8729

Report Date 2024-11-13

When -

Estimate -0.635

Actual -0.8729

Profitability

Profit Margin -

Operating Margin (TTM) -2344.68%

Management Effectiveness

Return on Assets (TTM) -

Return on Equity (TTM) -44.21%

Valuation

Trailing PE -	Forward PE -
Enterprise Value 142806406	Price to Sales(TTM) 105.52
Enterprise Value to Revenue 54.9	Enterprise Value to EBITDA -
Shares Outstanding 24289300	Shares Floating 4022556
Percent Insiders 20.64	Percent Institutions 89.04

Trailing PE -	Forward PE -	Enterprise Value 142806406	Price to Sales(TTM) 105.52
Enterprise Value to Revenue 54.9	Enterprise Value to EBITDA -	Shares Outstanding 24289300	Shares Floating 4022556
Percent Insiders 20.64	Percent Institutions 89.04

Analyst Ratings

Rating 4.8	Target Price 21.25	Buy 1
Strong Buy 4	Hold -	Sell -
Strong Sell -

Rating 4.8	Target Price 21.25	Buy 1	Strong Buy 4
Hold -	Sell -	Strong Sell -

About Artiva Biotherapeutics, Inc. Common Stock

Exchange	NASDAQ	Headquaters	San Diego, CA, United States
IPO Launch date	2024-07-19	President, CEO & Director	Dr. Fred Aslan M.D.
Sector	Healthcare	Website	https://www.artivabio.com
Industry	Biotechnology	Full time employees	82
Headquaters	San Diego, CA, United States
President, CEO & Director	Dr. Fred Aslan M.D.
Website	https://www.artivabio.com
Website	https://www.artivabio.com
Full time employees	82

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

https://www.upturn.io

Disclosure Privacy Policy Terms of Use Sitemap Contact Us

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.